Clinical and Economic Value of Tralokinumab (ADBRY®) for Patients With Moderate to Severe Atopic Dermatitis

Listen

0:00 / 0:00

This clinical brief was sponsored by LEO Pharma Inc.

This clinical brief is intended for payers, formulary committee members, drug selection panels, and other similar multidisciplinary individuals or entities. It contains health care economic information to aid in the selection of drugs for coverage or reimbursement. It is not intended for health care providers making individual prescribing decisions or for consumers.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Clinical and Economic Value of Tralokinumab (ADBRY®) for Patients With Moderate to Severe Atopic Dermatitis

Trending on AJMC

Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps

Senate Unveils Sweeping Bill to Reform 340B Drug Program

Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD

JAK Inhibitor Hesitancy and Step Therapy in Pediatric Alopecia Areata: A Q&A With Brittany Craiglow, MD

Brexpiprazole and Dextromethorphan-Bupropion: Mechanisms of Action and Key Clinical Trial Data for Approved Alzheimer's Disease Agitation Therapies